Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy

The present studies focused on defining the mechanisms by which anoikis-resistant (AR) mammary carcinoma cells can be reverted to a therapy-sensitive phenotype. AR mammary carcinoma cells had reduced expression of the toxic BH3 domain proteins BAX, BAK, NOXA, and PUMA. In AR cells expression of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruickshanks, Nichola, Hamed, Hossein A, Booth, Laurence, Tavallai, Seyedmehrad, Syed, Jahangir, Sajithlal, Gangadharan B, Grant, Steven, Poklepovic, Andrew, Dent, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926895/
https://www.ncbi.nlm.nih.gov/pubmed/24025251
http://dx.doi.org/10.4161/cbt.26234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926895/
https://www.ncbi.nlm.nih.gov/pubmed/24025251
http://dx.doi.org/10.4161/cbt.26234

Ejemplares similares